# Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)

> **NCT01954979** · PHASE1 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 56 (actual)

## Conditions studied

- Chronic Graft Versus Host Disease

## Interventions

- **DRUG:** Abatacept

## Key facts

- **NCT ID:** NCT01954979
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-27
- **Primary completion:** 2023-06-01
- **Final completion:** 2024-01-16
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2024-01-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01954979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01954979, "Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01954979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*